Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

(2022) Jeppe Sejerø Holm et al.   Nature Communications

Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

(2021) Li Wang et al.   CLINICAL CANCER RESEARCH

658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)

(2021) M.D. Galsky et al.   ANNALS OF ONCOLOGY

Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment

(2021) Robert Csaba Kiss et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation

(2021) Forat Lutfi et al.   Frontiers in Immunology

A conserved dendritic-cell regulatory program limits antitumour immunity

(2020) Barbara Maier et al.   NATURE

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

(2020) Patrick A. Ott et al.   CELL

A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

(2019) Matt D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer

(2019) Vid Leko et al.   JOURNAL OF IMMUNOLOGY

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

(2019) Padmanee Sharma et al.   CLINICAL CANCER RESEARCH

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

(2018) Matthew D. Galsky et al.   EUROPEAN UROLOGY

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

(2018) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial

(2018) Alex Rubinsteyn et al.   Frontiers in Immunology

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

(2015) Elizabeth R. Plimack et al.   EUROPEAN UROLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams

(2008) Tim Hulsen et al.   BMC GENOMICS